Genmab AS
$ 33.42
-0.89%
26 Dec - close price
- Market Cap 20,718,205,000 USD
- Current Price $ 33.42
- High / Low $ 33.96 / 33.31
- Stock P/E 14.66
- Book Value 93.41
- EPS 2.28
- Next Earning Report 2026-02-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.13 %
- ROE 0.29 %
- 52 Week High 33.96
- 52 Week Low 17.23
About
Genmab AS is a prominent biotechnology company based in Copenhagen, Denmark, dedicated to the development of innovative antibody therapeutics targeting oncology and other critical diseases. The company is recognized for its pioneering technologies and a strong pipeline of next-generation therapies, bolstered by strategic partnerships and collaborations with leading pharmaceutical firms. With a commitment to improving patient outcomes through targeted immunotherapies, Genmab is well-positioned to capitalize on growth opportunities in the rapidly advancing oncology market, making it an appealing investment for institutional investors looking for a leader in biopharmaceutical innovation.
Analyst Target Price
$37.81
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-12 | 2024-11-06 | 2024-08-08 | 2024-05-02 | 2024-02-14 | 2023-11-07 | 2023-08-03 | 2023-05-10 | 2023-02-22 |
| Reported EPS | 0.65 | 0.54 | 0.31 | 0.84 | 0.29 | 0.32 | 0.29 | 0.14 | 0.46 | 0.3 | 0.05 | 0.13 |
| Estimated EPS | 0.45 | 0.34 | 0.2 | 0.28 | 0.33 | 0.32 | 0.14 | 0.3 | 0.31 | 0.29 | 0.15 | 0.33 |
| Surprise | 0.2 | 0.2 | 0.11 | 0.56 | -0.04 | 0 | 0.15 | -0.16 | 0.15 | 0.01 | -0.1 | -0.2 |
| Surprise Percentage | 44.4444% | 58.8235% | 55% | 200% | -12.1212% | 0% | 107.1429% | -53.3333% | 48.3871% | 3.4483% | -66.6667% | -60.6061% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-11 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GMAB
2025-12-28 16:09:11
Staci Heise, formerly Director of Global Medical Affairs Oncology Publications at Daiichi Sankyo, has taken on a new role as Director of Medical Communications and Publications at Genmab. She announced her new position via a LinkedIn post, expressing her excitement for the opportunity.
2025-12-23 00:09:16
A/S Genmab recently acquired 212,177 shares of Merus (NASDAQ:MRUS) stock for a total value of over $20.5 million, increasing its position to 71,946,801 shares valued at approximately $6.98 billion. This is part of a series of purchases made by A/S Genmab between December 16th and 19th. Merus shares are trading near their 12-month high, with institutional ownership at 96.14% and analysts currently holding an average "Hold" rating with a $93.56 price target.
2025-12-19 01:08:58
A/S Genmab, a major shareholder in Merus (NASDAQ:MRUS), purchased 120,752 shares on December 16th for $11.7 million and an additional 150,795 shares on December 17th for $14.6 million, increasing its total ownership to 71,583,829 shares valued at approximately $6.94 billion. Despite these significant insider purchases, Merus shares traded down slightly to $96.80, and several analysts have recently downgraded the stock to "neutral" or "equal weight" with price targets around $97. The company remains unprofitable with a negative P/E ratio, though institutional investors hold a substantial 96.14% of the stock.
2025-12-18 03:09:06
Genmab (CPSE:GMAB) recently released new epcoritamab lymphoma data from ASH 2025, which has highlighted the drug's potential and provided investors with updated considerations. Despite a 32% year-to-date share price return, the stock trades close to consensus targets but at a discount to some intrinsic value models, leading investors to wonder if it's an overlooked growth story. The narrative suggests Genmab is 1.7% undervalued, with a fair value of $2054.66, driven by strong late-stage pipeline progress and expected revenue growth from innovative biologic therapies.
2025-12-16 11:08:52
Johnson & Johnson has received US priority review for a combination treatment featuring Tecvayli and Genmab's Darzalex after submitting new data. This accelerated review will apply to the therapy, leveraging Darzalex, which is a key growth product for the Danish company Genmab.
2025-12-13 20:09:31
Genmab's stock has rallied significantly in 2025, driven by pipeline progress and renewed interest in cancer therapies. Despite this, both Discounted Cash Flow and Price to Earnings analyses suggest the company may still be undervalued, with its intrinsic value estimated at $5,588 per share and a PE ratio below industry averages. Investors can use the Narratives framework to develop personalized valuations based on their own assumptions.
